Health-Economic Evaluation of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Treatment of Chronic Genotype 1 Hcv Infection in Germany

We evaluated long-term clinical and economic outcomes of ombitasvir/paritaprevir/ritonavir+dasabuvir±ribavirin (OBV/PTV/r+DSV±R) compared with other antiviral treatments for chronic hepatitis C (CHC) patients infected with genotype 1 (GT1) in Germany. A Markov cohort-simulation model for the German health-care setting was used to evaluate antiviral regimens: peginterferon+ribavirin (PR), telaprevir+PR, boceprevir+PR, sofosbuvir+PR,...